Boehringer Ingelheim inks third collab in four years with Danish biotech company

Danish biotech and contract research firm Gubra has signed a new agreement with German pharmaceutical giant Boehringer Ingelheim on the development of peptide compounds for treating obesity, according to a joint press announcement from the companies.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme recruits new CEO
For subscribers
Biomarin awaits crucial approvals and flat growth in 2021
For subscribers